greements based upon an initial forward price of approximately $50.75 per share on the closing date of this offering, Beckman Coulter would receive gross proceeds of $238.5 million upon settlement of the forward sale agreements, before deducting the underwriters' discount and estimated offering expenses. In addition, the forward purchasers have granted the underwriters of the common stock offering an option to purchase up to an additional 450,000 shares of Beckman Coulter's common stock to cover over-allotments; provided that Beckman Coulter may elect, in its sole discretion, in lieu of having the forward purchasers grant such option to the underwriters, to grant the underwriters an option to purchase from Beckman Coulter an equal number of shares on the same terms.
The offering is being made under Beckman Coulter's existing shelf registration statement filed with the Securities and Exchange Commission. This press release is neither an offer to sell nor a solicitation of an offer to buy any of the common stock or any other security of Beckman Coulter, nor shall there be any sale of the common stock in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration of qualification under the securities laws of any such jurisdiction. When available, copies of the prospectus and related prospectus supplement may be obtained from Morgan Stanley & Co. Incorporated, Prospectus Department, 1585 Broadway, New York, NY 10036 and Goldman Sachs & Co., 85 Broad Street, New York, NY 10004 Attention: Prospectus Department (212-902-1171).
Certain statements in this news release may be deemed to include forward-looking statements, such as statements that relate to the common stock offering and whether Beckman Coulter will consummate the offering. Forward-looking statements are typically identified by words or phrases, such as "believe," "expect," "anticipate," "intend," "estimate," "may increase," "Page: 1 2 3 Related biology technology :1
. Beckman Coulter Prices $500 Million Senior Notes Offering2
. Beckman Coulter to Present at the Bank of America and Merrill Lynch Healthcare Conference3
. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share4
. Beckman Coulter Announces First Quarter 2009 Results5
. Beckman Coulter Announces First Quarter 2009 Earnings to be Released on Tuesday, April 28, 2009, After Market Closes6
. Beckman Coulter to Webcast Annual Stockholders Meeting7
. Beckman Coulter to Acquire Lab-Based Diagnostics Business From Olympus Corporation8
. Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals9
. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share10
. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes11
. Beckman Coulter to Present at the 27th Annual J.P. Morgan Healthcare Conference